$0.00
$0.43
bear $0.00
base $0.02
bull $0.43
margin of safety $0.10
market price* $0.24
Business condition attached to the margin of safety
The company stops consuming its cash, either by halting trial spending and committing to return or preserve the remaining cash, or by signing a partnership for CTIM-76 or CT-202 whose committed payments fund development.
Context Therapeutics is a Philadelphia biotech with fifteen employees. It develops T-cell engaging antibodies for solid tumours. These are bispecific drugs that tie a patient's T cells to a marker on cancer cells. It has no revenue and no approved product. The lead drug is CTIM-76, which targets Claudin 6 in ovarian, endometrial and testicular cancers. It is in a Phase 1 trial, received FDA Fast Track status in April 2026, and in June 2026 reported a 29% confirmed response rate in platinum-resistant ovarian cancer. The second drug is CT-202, a Nectin-4 x CD3 antibody licensed from BioAtla in September 2024. Its first patient was dosed in September 2026. A third drug, CT-95, which targets mesothelin and was bought in 2024 from the assignee of the failed Link Immunotherapeutics, was discontinued in mid-2026. In May 2026 the BioAtla licence was amended to a $4.5 million payment plus a final $2.0 million, with no further milestones or royalties. That removes up to $122.5 million of contingent milestones and means any CT-202 success belongs wholly to Context. The business has never produced cash. Owner earnings, meaning operating cash flow less working-capital swings, stock compensation and capital spending, were -$7.1M (2021), -$14.4M (2022), -$23.9M (2023), -$12.0M (2024) and -$34.1M (2025). We measure from 2024, when today's pipeline was assembled. The median of 2024-2025 is about -$23M a year, but the current rate is higher. The first half of 2026 used $23.0M, including the $4.5M BioAtla payment. In 2025 the cash burn grew about 185%, and our first-year assumption does not improve on that: spending runs at roughly $30M a year after CT-95 was dropped. The company paid about $17M for drug licences in 2024-2026. Accounting treats these as investing outflows rather than operating costs. We do not deduct them from owner earnings, but they are real cash, and they are why cash fell faster than owner earnings suggest. There is no debt and no interest. What the company owns today is $43.0M of cash (June 30, 2026), about $0.45 per share on 95.2M shares, which include pre-funded warrants. Of that, $2.0M is already owed to BioAtla. The 10-Q says this cash funds operations into the fourth quarter of 2027. In other words, management plans to spend essentially all of it on CTIM-76 and CT-202 trials. No drug has a partner, a sale contract or any committed revenue. Early-stage cancer drugs, even with encouraging Phase 1 response rates, usually do not reach market. So we credit the pipeline with no value in any case. That is not a claim that it is worthless. It means nothing yet puts cash in the bag. Bear case ($0.00): CTIM-76's early responses do not hold up in larger cohorts, the planned spending runs through 2027, and nothing is left for today's shareholders. The business is worth nothing and owes nothing beyond ordinary payables, so shareholders end at about zero. Any further funding would be raised on heavily dilutive terms. Base case ($0.02): the stated plan runs as written. About $41M is spent on trials between mid-2026 and late 2027, the drugs do not generate committed cash in that window, and about $2M of present value is left over. That works out to roughly two cents a share. The business is worth close to nothing, owes no debt, and equity is worth the small residual. Bull case ($0.43): CTIM-76 and CT-202 data are strong enough that the money spent buys assets worth at least what they cost, for example a licensing deal on normal terms. Shareholders then keep the full value of today's net cash, $43.0M less the $2.0M BioAtla payment, or about $0.43 a share. We do not credit a larger deal or approval, because no such agreement exists. What the shares appear to be worth: close to zero on the company's current plan, and at most about their net cash if the spending pays off. The cash is being consumed at about $30M a year, so price alone does not create a margin of safety. The margin-of-safety price applies only if the company stops spending the cash or a partner starts paying for development. At that point the margin-of-safety price is about $0.10 a share, well under the cash that would then be protected. The shares closed below $1.00 for 30 business days and Nasdaq issued a notice on July 31, 2026. The company has until January 25, 2027 to regain compliance, most likely through a reverse split. This is the second such notice in about a year. The company previously regained compliance after an August 2025 notice. What would make this analysis wrong: a signed partnership with upfront and milestone payments for CTIM-76 or CT-202, which would add value we cannot credit today. Or the reverse: an equity raise at current prices before any data-driven deal, which would move value from existing holders to new ones.